Thomas Jandl, MD
Hematology & Oncology · Stony Brook, NYNPI 1306265301
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $643 of the $884 with a category attached, or 72.7%. It is spread thinly across 16 manufacturers, the largest accounting for just 18.2%. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 30 payments — averaging $29.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$161
- Pfizer$151
- AstraZeneca$143
- Daiichi Sankyo Inc.$68
- Regeneron$61
- Sanofi-aventis U.S. LLC$44
- plus $256 from 10 others
Across 105 payments — averaging $19,319 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.2M
- Regeneron$682K
- Astrazeneca UK Limited$161K
- Karyopharm Therapeutics Inc.$24K
- Janssen Research & Development, LLC$8K
What the payments were for
- Food & beverage$64373%
- Education$24127%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $161 |
| Pfizer | 8 | $151 |
| AstraZeneca(2 entities) | 2 | $143 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Regeneron | 2 | $61 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| Bristol Myers Squibb | 2 | $35 |
| Melinta Therapeutics, LLC | 1 | $30 |
| AbbVie | 1 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Pharmaessentia USA Corporation | 1 | $27 |
| Genmab U.S., Inc. | 1 | $27 |
| Seagen Inc. | 1 | $26 |
| Sobi, Inc | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$884 in reported general payments places this provider in the 40th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 17 | $442 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Stony Brook
- Jules CohenStony Brook$557K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.